What does an mTOR inhibitor do?
What does an mTOR inhibitor do?
Mammalian target of rapamycin (mTOR) inhibitors block the activity of the mammalian target of rapamycin. Mammalian target of rapamycin is a protein kinase, which regulates growth factors that stimulate cell growth and angiogenesis. In certain cancers the mTOR pathway is more active.
What is mTOR explain its connection to cancer?
mTOR complex is recently depicted as a nutrient sensor in metabolism of cancer, especially on glucose and amino acid, nucleotide, fatty acid and lipid, growth factors and other stresses. Nutrient sensing mainly activates mTORC1 and the metabolic changes in cancer cells sustain mTOC1 activation in turn [2,22,23,88].
What drugs are mTOR inhibitors?
Recently rapamycin has shown effective in the inhibition of growth of several human cancers and murine cell lines. Rapamycin is the main mTOR inhibitor, but deforolimus (AP23573), everolimus (RAD001), and temsirolimus (CCI-779), are the newly developed rapamycin analogs.
Is rapamycin used to treat cancer?
Rapamycin is approved to treat renal cancer and is in clinical trials to treat various other cancers, but the molecular determinants of drug response are unknown. Preclinical data show that loss of the tumour suppressor PTEN sensitizes tumours to the inhibition of mammalian target of rapamycin (mTOR).
How do I reduce mTOR?
Metformin and resveratrol inhibit mTOR through upstream pathways, inhibiting the mitochondrial complex I activity and increasing AMPK respectively. Rapamycin, and rapalogs, on the other hand inhibit mTOR directly.
What kind of cancer can a mTOR inhibitor treat?
In addition to treating pNET, mTOR inhibitors may play a role in a variety of other cancers. In fact, the FDA has approved everolimus for the treatment of some patients with renal (kidney) cell carcinoma and breast cancer.
Are there any drugs that block the mTOR pathway?
In certain cancers the mTOR pathway is more active. Mammalian target of rapamycin (mTOR) inhibitors are used in treatment of renal cancer and is being studied for use in other types of cancers.
Are there any mTORC1 inhibitors for renal cell cancer?
Several mTORC1 inhibitors are in clinical trials for various tumor subtypes, including everolimus (Afinitor), temsirolimus (Torisel), and ridaforolimus (AP23573). Temsirolimus was the first rapalog approved by the US Food and Drug Administration (FDA); it was approved in 2007 for the treatment of advanced renal cell cancer.
How are activated mTOR Raptors used to treat cancer?
Activated mTOR-raptor complex 1 (mTORC1) results in enhanced protein synthesis and also inhibits PI3K signaling. Activated mTOR-rictor complex 2 (mTORC2) promotes cell survival. [4] Activating PI3K mutations are frequent in human cancers and have been identified as oncogenic, making this pathway an attractive therapeutic target in cancer. [5]